KR102055859B1 - 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합 - Google Patents

아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합 Download PDF

Info

Publication number
KR102055859B1
KR102055859B1 KR1020147018413A KR20147018413A KR102055859B1 KR 102055859 B1 KR102055859 B1 KR 102055859B1 KR 1020147018413 A KR1020147018413 A KR 1020147018413A KR 20147018413 A KR20147018413 A KR 20147018413A KR 102055859 B1 KR102055859 B1 KR 102055859B1
Authority
KR
South Korea
Prior art keywords
acamprosate
delete delete
dose
composition
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147018413A
Other languages
English (en)
Korean (ko)
Other versions
KR20140121394A (ko
Inventor
윌리암 디. 컨즈
베리 에스. 포겔
케이-라이 퐁
산-라웅 쵸우
데이비드 웡
에드워드 린
Original Assignee
싱크로뉴런 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 싱크로뉴런 인코포레이티드 filed Critical 싱크로뉴런 인코포레이티드
Publication of KR20140121394A publication Critical patent/KR20140121394A/ko
Application granted granted Critical
Publication of KR102055859B1 publication Critical patent/KR102055859B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020147018413A 2011-12-02 2012-12-02 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합 Active KR102055859B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161566550P 2011-12-02 2011-12-02
US61/566,550 2011-12-02
US201261649137P 2012-05-18 2012-05-18
US61/649,137 2012-05-18
PCT/US2012/067507 WO2013082573A1 (en) 2011-12-02 2012-12-02 Acamprosate formulations, methods of using the same, and combinations comprising the same

Publications (2)

Publication Number Publication Date
KR20140121394A KR20140121394A (ko) 2014-10-15
KR102055859B1 true KR102055859B1 (ko) 2019-12-13

Family

ID=48536156

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147018413A Active KR102055859B1 (ko) 2011-12-02 2012-12-02 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합

Country Status (14)

Country Link
EP (1) EP2785337B1 (https=)
JP (1) JP6407720B2 (https=)
KR (1) KR102055859B1 (https=)
CN (1) CN104379138B (https=)
AU (1) AU2012345659B2 (https=)
BR (1) BR112014013374B1 (https=)
CA (1) CA2863265C (https=)
HK (2) HK1199841A1 (https=)
IL (1) IL232935B (https=)
MX (1) MX375183B (https=)
RU (1) RU2671399C2 (https=)
SG (1) SG11201403785UA (https=)
WO (1) WO2013082573A1 (https=)
ZA (1) ZA201404826B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2014197744A1 (en) * 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3946303A4 (en) * 2019-04-03 2022-12-14 Synchroneuron Inc. FORMULATING
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CA3150474A1 (en) * 2019-10-11 2021-04-15 Geraint Iwan Davies Drug dosage determination devices and methods
CN116867494A (zh) * 2021-02-15 2023-10-10 凯麦拉医疗公司 Irak4降解剂和其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426087B1 (en) 1998-02-23 2002-07-30 Merck Patent Gesellschaft Mit Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036064A2 (en) * 1998-01-13 1999-07-22 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
MXPA04010956A (es) * 2003-01-30 2005-01-25 Roehm Gmbh Forma de dosis farmaceutica y metodo para la produccion de la misma.
RU2284814C1 (ru) * 2005-04-08 2006-10-10 Государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Министерства здравоохранения Российской Федерации" Способ лечения оптического неврита при оптикохиазмальном арахноидите в стадии ремиссии
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US20100081672A1 (en) * 2006-12-07 2010-04-01 Schering Corporation Ph sensitive matrix formulation
DE102007009242A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
JP5714562B2 (ja) * 2010-02-22 2015-05-07 第一三共株式会社 経口用徐放性固形製剤
CN101987081B (zh) * 2010-07-16 2012-08-08 钟术光 一种控释制剂
MX346203B (es) * 2010-09-28 2017-03-09 Depomed Inc Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426087B1 (en) 1998-02-23 2002-07-30 Merck Patent Gesellschaft Mit Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent

Also Published As

Publication number Publication date
SG11201403785UA (en) 2014-10-30
IL232935A0 (en) 2014-07-31
CA2863265C (en) 2020-04-14
MX2014006574A (es) 2015-02-10
ZA201404826B (en) 2016-07-27
EP2785337B1 (en) 2021-01-20
CN104379138A (zh) 2015-02-25
JP2015500812A (ja) 2015-01-08
KR20140121394A (ko) 2014-10-15
RU2014126879A (ru) 2016-01-27
JP6407720B2 (ja) 2018-10-17
AU2012345659A1 (en) 2014-07-24
HK1207563A1 (en) 2016-02-05
MX375183B (es) 2025-03-06
BR112014013374B1 (pt) 2022-10-11
BR112014013374A8 (pt) 2021-08-31
EP2785337A1 (en) 2014-10-08
CN104379138B (zh) 2021-12-07
IL232935B (en) 2020-11-30
WO2013082573A1 (en) 2013-06-06
RU2671399C2 (ru) 2018-10-31
AU2012345659A8 (en) 2014-08-07
CA2863265A1 (en) 2013-06-06
EP2785337A4 (en) 2015-04-22
AU2012345659B2 (en) 2017-09-28
BR112014013374A2 (pt) 2017-06-13
HK1199841A1 (en) 2015-07-24

Similar Documents

Publication Publication Date Title
US10512621B2 (en) Methods of treating posttraumatic stress disorder with acamprosate salts
US20150250746A1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
JP5421511B2 (ja) 胃に留まるガバペンチン投薬を使用する処置方法
JP7323451B2 (ja) フロルグルシノールおよびトリメチルフロログルシノールの医薬製剤
KR102055859B1 (ko) 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합
JP2009526825A (ja) 経口投与用の多微粒子状医薬製剤
EP1485071A2 (fr) Comprimes a base de microcapsules a liberation modifiee
TW200427448A (en) Controlled release preparations comprising tramadol and topiramate
WO2007106960A1 (en) Controlled-release floating dosage forms
WO2010023690A2 (en) Prolonged release formulation of amisulpride
JP2019533672A (ja) メラトニンミニタブレットおよびその製造方法
TW200800155A (en) Gastric retentive gabapentin dosage forms and methods for using same
US20070112075A1 (en) Stable pharmaceutical formulations containing escitalopram and bupropion
US20080014261A1 (en) Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20080008772A1 (en) Narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
HK1259508B (zh) 氘代多潘立酮组合物和用於治疗病症的方法
Jethara et al. Aperito Journal of Drug Designing And Pharmacology

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140702

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171116

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190208

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190916

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20191209

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20191210

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20221027

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20221027

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20241029

Start annual number: 6

End annual number: 6